Carina C. D. Joe
A5023652131- Virus-based gene therapy research
- SARS-CoV-2 and COVID-19 Research
- CAR-T cell therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- Hepatitis B Virus Studies
- Immunotherapy and Immune Responses
- Hepatitis C virus research
- Monoclonal and Polyclonal Antibodies Research
- COVID-19 Clinical Research Studies
- Bacteriophages and microbial interactions
- Retinal and Optic Conditions
- SARS-CoV-2 detection and testing
- Long-Term Effects of COVID-19
- Protein purification and stability
- COVID-19 and Mental Health
- Vaccine Coverage and Hesitancy
- HIV Research and Treatment
- Biomedical and Engineering Education
- vaccines and immunoinformatics approaches
- Glycosylation and Glycoproteins Research
- Viral Infections and Immunology Research
- Tuberculosis Research and Epidemiology
CSIRO Manufacturing
2024
Jenner Institute
2020-2023
Health Sciences and Nutrition
2019-2023
Commonwealth Scientific and Industrial Research Organisation
2019-2023
University of Oxford
2020-2023
RMIT University
2019-2023
SummaryBackgroundA safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of COVID-19 pandemic. We evaluated safety efficacy ChAdOx1 nCoV-19 in a pooled interim analysis four trials.MethodsThis includes data from ongoing blinded, randomised, controlled trials done across UK, Brazil, South Africa. Participants aged 18 years older were randomly assigned (1:1) or (meningococcal group A,...
Older adults (aged ≥70 years) are at increased risk of severe disease and death if they develop COVID-19 therefore a priority for immunisation should an efficacious vaccine be developed. Immunogenicity vaccines is often worse in older as result immunosenescence. We have reported the immunogenicity novel chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19 (AZD1222), young adults, now describe safety this wider range participants, including aged 70 years older.In report phase 2 component...
The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given an interval 4-12 weeks. planned roll-out in will involve vaccinating people high-risk categories their first dose immediately, delivering second 12 weeks later. Here, we provide both further prespecified pooled analysis trials exploratory analyses impact on immunogenicity efficacy extending...
Abstract Manufacturing has been the key factor limiting rollout of vaccination during COVID‐19 pandemic, requiring rapid development and large‐scale implementation novel manufacturing technologies. ChAdOx1 nCoV‐19 (AZD1222, Vaxzevria) is an efficacious vaccine against SARS‐CoV‐2, based upon adenovirus vector. We describe a process for production this others same platform, including features to facilitate very production. discuss economics “distributed manufacturing” approach we have taken...
Abstract Distribution of vaccines which require refrigerated or frozen storage can be challenging and expensive. The adenovirus vector platform has been widely used for COVID-19 while several further candidate using the are in clinical development. In current liquid formulations, adenoviruses distribution at 2–8 °C. development formulations suitable ambient temperature would advantageous. Previous peer-reviewed reports lyophilization relatively limited. Here, we report a formulation process...
Tuberculosis (TB) remains a significant public health challenge worldwide. Currently, Bacillus Calmette-Guerin (BCG) is the only vaccine available for TB prophylaxis. However, efficacy of BCG against adult pulmonary considered inconsistent. This condition encourages researchers to look more effective options, such as subunit vaccines. requires development protect active in productive and ages. There an urgent need vaccines, Calmette-Guérin currently has inconsistent partially adults....
Nanoparticles show great promise as a platform for developing vaccines the prevention of infectious disease. We have been investigating method whereby nanocapsules can be formulated from protein, such that final capsules contain only cross-linked protein itself. Such are made using silica templating system and customised in terms size porosity. Here we compare construction characteristics four different proteins: one model (ovalbumin) three disease pathogens, namely influenza virus,...
Abstract The Coalition for Epidemic Preparedness Innovations' “100‐day moonshot” aspires to launch a new vaccine within 100 days of pathogen identification, followed by large‐scale availability the “second hundred days.” Here, we describe work optimize adenoviral vector manufacturing rapid response, minimizing time clinical trial and first supply, maximizing output from available footprint. We virus seed expansion workflow that allows release trials 60 antigen sequence globally distributed...
Abstract The Coalition for Epidemic Preparedness Innovations’ ‘100-day moonshot’ aspires to launch a new vaccine within 100 days of pathogen identification. Here, we describe work optimize adenovirus vector manufacturing rapid response, by minimizing time clinical trial and first large-scale supply, maximizing the output from available footprint. We viral seed expansion workflow that allows release trials 60 antigen sequence identification, followed globally distributed sites further 40...
Virus-like particles (VLPs), composed of the small hepatitis B virus surface antigen (HBsAgS), are antigenic components (HBV) vaccine and represent backbones for a chimeric anti-malaria various candidates. Biological vectors have to face pre-existing anti-vector immune responses due previous exposure. Vector recognition after natural infections or vaccinations can result in unwarranted outcomes, with compromising effects on clinical outcomes. In order evaluate impact anti-HBsAgS response, we...
The COVID-19 pandemic has caused millions of deaths and devastated communities across the globe. Vaccines will play a key role in bringing under control, with successful clinical trials, authorizations roll-out having now occurred several countries. However, large-scale manufacturing such vaccines remains bottleneck to delivering doses billions people at risk infection, as well producing new versions that target variants. Here we discuss current status manufacturing, focusing on...